Abstract
Lysosomal storage diseases (LSDs) is a group consisting of over 50 disorders caused mostly by dysfunctions of lysosomal proteins and resultant accumulation of particular compounds inside cells and extracellular volumes in affected organisms. Genetic diseases are among the most difficult targets for medical treatment. Nevertheless, understanding of molecular bases of LSDs made it possible to develop novel procedures of treatment, employing molecular medicine. Although various therapeutic approaches have been proposed, and some of them were introduced into clinical practice, none of them was found to be effective in correcting all symptoms in treated patients. Central nervous system and skeleton appear to be the most difficult targets to be improved. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy. In this review, we present and discuss current stage of various combination therapies for LSDs, based on already available published data.
Keywords: Combined therapies, enzyme replacement therapy, gene therapy, hematopoietic cell transplantation, lysosomal storage diseases, small molecular chaperones, substrate reduction therapy.
Current Molecular Medicine
Title:Combined Therapies for Lysosomal Storage Diseases
Volume: 15 Issue: 8
Author(s): M. Gabig-Cimińska, J. Jakóbkiewicz-Banecka, M. Malinowska, A. Kloska, E. Piotrowska, I. Chmielarz, M. Moskot, A. Węgrzyn and G. Węgrzyn
Affiliation:
Keywords: Combined therapies, enzyme replacement therapy, gene therapy, hematopoietic cell transplantation, lysosomal storage diseases, small molecular chaperones, substrate reduction therapy.
Abstract: Lysosomal storage diseases (LSDs) is a group consisting of over 50 disorders caused mostly by dysfunctions of lysosomal proteins and resultant accumulation of particular compounds inside cells and extracellular volumes in affected organisms. Genetic diseases are among the most difficult targets for medical treatment. Nevertheless, understanding of molecular bases of LSDs made it possible to develop novel procedures of treatment, employing molecular medicine. Although various therapeutic approaches have been proposed, and some of them were introduced into clinical practice, none of them was found to be effective in correcting all symptoms in treated patients. Central nervous system and skeleton appear to be the most difficult targets to be improved. Therefore, a proposal appeared that perhaps no single therapeutic procedure may be fully effective in treatment of LSD patients, and only combination of two or more approaches could be a successful therapy. In this review, we present and discuss current stage of various combination therapies for LSDs, based on already available published data.
Export Options
About this article
Cite this article as:
Gabig-Cimińska M., Jakóbkiewicz-Banecka J., Malinowska M., Kloska A., Piotrowska E., Chmielarz I., Moskot M., Węgrzyn A. and Węgrzyn G., Combined Therapies for Lysosomal Storage Diseases, Current Molecular Medicine 2015; 15 (8) . https://dx.doi.org/10.2174/1566524015666150921105658
DOI https://dx.doi.org/10.2174/1566524015666150921105658 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Pharmacogenetics Research Developments in Africa: A Focus on Malawi
Current Pharmacogenomics and Personalized Medicine A Survey on the Usage of Supplements in Canadian Patients Living with HIV
Current HIV Research Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Commentary: The Effects of Psychological Stress on Microglial Cells in the Brain
CNS & Neurological Disorders - Drug Targets Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Strategies to Develop Allergy Immunotherapeutics with Applications of Directed Molecular Evolution
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Glutamate-Based Drugs for the Treatment of Clinical Depression
Central Nervous System Agents in Medicinal Chemistry Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review
Current Medicinal Chemistry Topical Calcineurin Inhibitors, Pimecrolimus and Tacrolimus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics